Cue Health Inc.

Biopharmas above $5B in market cap are up, but everyone else languishes

Plus: BioCentury’s Bernstein joins C-Path board and updates from Marengo and Certara

Plus Apple’s Tsay becomes CMO at Cue Health, and updates from Nouscom, Deka, Cogitativo and more

Plus 10x Genomics hires Wilbur to head commercial, and updates from Immune-Onc, PathAI, Sherlock and more

Cue the IPO, plus DMD data, Jasper SPAC, GeNeuro-Northwestern, Everest-AbCellera CinRx newco and more

Plus: Mavilio, Loggia join Orchard and updates from PMV, Verseau, Apexigen, VectivBio, Protagonist and more

In the wake of sexual harassment allegations, former Operation Warp Speed leader Moncef Slaoui has resigned as chairman of Vaxcyte Inc. (NASDAQ:PCVX) and as CSO and adviser at Centessa Pharmaceuticals

FDA’s new guidelines on COVID-19 screening tests provide a clearer and more streamlined path for a product use case whose regulatory status has been largely out of alignment with its

FDA’s first authorization of an over-the-counter molecular test marks a turning point for COVID-19 screening via a system that encourages repeat home testing. Performance metrics reported by

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test. A fact sheet released by HHS Tuesday showed the U.S. federal government has